in the data collection interface and greater experience with the data collection for partners.15
Conclusion: Because of limitations in the available financial data, it is difficult to fully assess the amount and distribution by program area and partner type of the annual direct investment of PEPFAR in partner countries. PEPFAR would benefit from the collection and reporting of financial data that not only serves for accounting purposes but also are more closely aligned with programmatic data and program implementation. These data are critical for PEPFAR and external stakeholders to more easily and effectively understand how well PEPFAR is being implemented and how PEPFAR’s investment relates to both the targets and goals of PEPFAR-supported programs and the broader goal of transitioning to more sustainable management of the response to HIV in partner countries. To this end, the committee, while acknowledging the realities of the additional reporting burden, supports OGAC’s request to collect more information from implementing partners on PEPFAR program expenditures.
As described above, most PEPFAR funding is appropriated and budgeted for activities within partner countries. In addition to understanding how PEPFAR funding is distributed among the different program priorities and different mechanisms and partners for implementation, the committee was interested in assessing the characteristics of the countries that have received PEPFAR funding over time and the distribution of funding across these countries. PEPFAR’s authorizing legislation recognized the need “to turn the tide against AIDS” in African and Caribbean countries most affected by HIV/AIDS.16 The legislation stated that the required Five-Year Strategy should “establish priorities for the distribution of resources based on factors such as the size and demographics of the population with HIV/AIDS [. . .] and the needs of that population and the existing infrastructure or funding levels that may exist.”17 As described in Chapter 1, at PEPFAR’s inception bilateral USG HIV/AIDS programs encompassed activities in more than 100 countries, and since FY 2004, at least 112 countries have received PEPFAR support. However, the authorizing legislation designated 14 specific countries in which all USG HIV-related activities should be
16Supra, note 7 at 2(28).
17Supra, note 7 at 101(a)(9).